1. 7TM Pharma (2008a). Results from a phase I/II clinical study with the drug candidate Obinepitide for the treatment of obesity. 7TM Pharma: Press release November 28, 2007. Retrieved June 2nd, 2009, from http://www.7tm.com/News/News_Archive.aspx?M=News&PID=45&NewsID=9
2. 7TM Pharma (2008b). TM Pharma has initiated phase I/IIa clinical trial with TM30339 for the treatment of obesity and related metabolic disorders. 7TM Pharma: Press Release. September 2nd, 2008. Retrieved June 2nd, 2009 from http://www.7tm.com/News/News_Archive.aspx?M=News&PID=45&NewsID=45
3. 7TM Pharma (n.d.). Obinepitide. 7TM Pharma Retrieved June 2nd, 2009, from http://www.7tm.com/R-D/Metabolic_Disorders/Obinepitide.aspx
4. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway;Abbott;Brain Res,2005
5. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake;Abbott;Brain Res,2005